2025 : 10 : 14
Fariborz Rahimi

Fariborz Rahimi

Academic rank: Associate Professor
ORCID:
Education: PhD.
ScopusId:
HIndex: 0/00
Faculty: Faculty of Engineering
Address:
Phone: 04137745000-1630

Research

Title
Co-delivery of doxorubicin and conferone by novel pH-responsive β-cyclodextrin grafted micelles triggers apoptosis of metastatic human breast cancer cells
Type
JournalPaper
Keywords
drug delivery, co-delivery, breast cancer cells
Year
2021
Journal Scientific Reports
DOI
Researchers Akram Rahmani ، Fariborz Rahimi ، Mehrdad Iranshahi ، Houman Kahroba ، Amir Zarebkohan ، Mehdi Talebi ، Roya Salehi ، Hassan Zavvar Mousavi

Abstract

Adjuvant-aided combination chemotherapy is one of the most effective ways of cancer treatment by overcoming the multidrug resistance (MDR) and reducing the side-effects of anticancer drugs. In this study, Conferone (Conf) was used as an adjuvant in combination with Doxorubicin (Dox) for inducing apoptosis to MDA-MB-231 cells. Herein, the novel biodegradable amphiphilic β-cyclodextrin grafted poly maleate-co-PLGA was synthesized by thiol-ene addition and ring-opening process. Micelles obtained from the novel copolymer showed exceptional properties such as small size of around 34.5 nm, CMC of 0.1 μg/mL, and cell internalization of around 100% at 30 min. These novel engineered micelles were used for combination delivery of doxorubicin-conferone with high encapsulation efficiency of near 100% for both drugs. Our results show that combination delivery of Dox and Conf to MDA-MB-231 cells had synergistic effects (CI < 1). According to cell cycle and Annexin-V apoptosis analysis, Dox-Conf loaded micelle significantly induce tumor cell apoptosis (more than 98% of cells population showed apoptosis at IC50 = 0.259 μg/mL). RT-PCR and western-blot tests show that Dox-Conf loaded βCD-g-PMA-co-PLGA micelle induced apoptosis via intrinsic pathway. Therefore, the unique design of multi-functional pH-sensitive micelles open a new perspective for the development of nanomedicine for combination chemo-adjuvant therapy against malignant cancer.